Deciphering Ligand Selectivity of HCAR3: Insights from Structural Biology

Study Background and Research Question

Hydroxycarboxylic acid receptors (HCARs)—notably HCAR2 (GPR109A) and HCAR3—are prototypical metabolite-sensing G-protein coupled receptors (GPCRs) with established roles in regulating lipid metabolism and signaling. Pharmacological activation of HCAR2 is a validated strategy for correcting dyslipidemia, but is limited by adverse effects such as cutaneous flushing. In contrast, HCAR3 remains less characterized, despite its potential as a safer target for hypolipidemic intervention. The central research question addressed by Ye et al. (2025) is: What are the structural determinants governing agonist recognition and selectivity in HCAR3, and how can these be leveraged to design better metabolic disorder therapeutics?

Key Innovation from the Reference Study

The notable contribution of the study lies in presenting the first high-resolution cryo-electron microscopy (cryo-EM) structures of HCAR3 in complex with four selective agonists, including (R)-5-methyl-4-oxo-5-phenyl-4,5-dihydrofuran-2-carboxylic acid (commonly known as Acifran). By determining the HCAR3-Gi complex structures at resolutions between 3.05 Å and 3.31 Å, the authors systematically elucidate how these agonists interact with the orthosteric binding pocket and how specific residues confer ligand selectivity. The inclusion of both HCAR3 and HCAR2 complexes with Acifran enables comparative analysis, shedding light on the molecular underpinnings of receptor-specific activation and side effect profiles.

Methods and Experimental Design Insights

To achieve these structural insights, the research team employed advanced cryo-EM techniques. HCAR3 and HCAR2 receptors were expressed in Sf9 insect cells as complexes with heterotrimeric Gi proteins. The following agonists were co-crystallized with the target receptors: compound 6O, D-phenyllactic acid (PLA), IBC293, and Acifran. The resulting complexes were purified and subjected to cryo-EM, yielding density maps at near-atomic resolution (e.g., Acifran-HCAR3 at 3.18 Å and Acifran-HCAR2 at 2.72 Å).

Functional validation was performed using cAMP inhibition assays in HEK-293 cells, enabling the linkage of structural observations to receptor activation profiles. The data sets, including 3D density maps and atomic coordinates, were deposited in public databases (Electron Microscopy Data Bank and Protein Data Bank), ensuring transparency and reproducibility (Ye et al., 2025).

Protocol Parameters

• Receptor Complex Expression: HCAR3-Gi or HCAR2-Gi complexes were expressed in Sf9 cells using baculovirus-mediated expression systems.
• Agonist Preparation: Agonists, including Acifran, were prepared at concentrations sufficient for stable receptor binding (details on optimal solubility provided in product information).
• Cryo-EM Grid Preparation: Complexes were vitrified and imaged on a Titan Krios microscope, enabling sub-4 Å resolution structure determination.
• Functional Assay: cAMP inhibition was quantified in HEK-293 cells expressing HCAR3 or HCAR2 following agonist treatment.

Core Findings and Why They Matter

The study demonstrates that HCAR3 exhibits unique ligand recognition features distinct from HCAR2, despite their high sequence similarity. Key structural findings include:

• Binding Pocket Architecture: The orthosteric pocket of HCAR3 comprises two subregions (R1 and R2). Selectivity and potency are influenced by the extent to which an agonist occupies both regions.
• Residue-Specific Interactions: Aromatic π–π stacking with F107^3.32 (phenylalanine at position 107) in HCAR3, as opposed to L107^3.32 (leucine) in HCAR2, underlies the receptor’s differential ligand affinity. Additional differences at V/L83^2.60, Y/N86^2.63, and S/W91^2.48 modulate the size and shape of the pocket.
• Acifran’s Binding Mode: Acifran forms key hydrogen bonds and hydrophobic interactions within HCAR3, but demonstrates altered binding geometry in HCAR2, explaining differences in potency and selectivity. This insight is critical for the rational development of HCAR3-targeted hypolipidemic agents that can minimize HCAR2-mediated side effects (Ye et al., 2025).

These mechanistic revelations support the design of next-generation agents for lipid metabolism regulation and metabolic disorder research, with the potential to avoid adverse effects linked to current therapies.

Comparison with Existing Internal Articles

Several internal resources complement and contextualize the findings of Ye et al. (2025):

• Structural Insights into HCAR3 Agonist Binding and Selectivity distills similar cryo-EM data, reinforcing that ligand selectivity is mediated by pocket architecture and residue-specific interactions. The reference study significantly extends these insights with direct visualization of multiple agonist-receptor complexes, including Acifran.
• Acifran’s Structural Basis and Selectivity in Lipid Regulation details the role of Acifran as a hypolipidemic agent for lipid metabolism research, highlighting its value in dissecting lipid signaling pathway modulation. Ye et al. (2025) provide the definitive structural rationale for these functional properties, moving discussions from theoretical models to direct molecular observation.
• For application strategies in metabolic disorder research, Acifran: Unveiling Novel Mechanisms in Lipid Signaling Pathways discusses how selective receptor agonists like Acifran can be leveraged to probe signaling networks. The reference paper now provides the structural context for these applications.

Limitations and Transferability

Despite the high resolution and robust functional correlation, several limitations should be acknowledged:

• Cellular Context: Structural data were obtained in non-human (Sf9) expression systems; while receptor folding and coupling are preserved, post-translational modifications may differ from native human tissues.
• Agonist Spectrum: Only a subset of chemically diverse agonists was profiled. Broader screening could reveal additional determinants of selectivity.
• Downstream Pathways: Functional assays focused on cAMP inhibition, a proximal readout. Comprehensive mapping of lipid signaling pathway modulation or metabolic outcomes was outside the study’s scope.
• Translational Implications: While the findings are foundational for rational drug design, the direct translation to clinical efficacy or avoidance of HCAR2-specific adverse effects will require further in vivo validation.

Research Support Resources

Researchers aiming to replicate or extend this work can access Acifran—chemically designated as (R)-5-methyl-4-oxo-5-phenyl-4,5-dihydrofuran-2-carboxylic acid (SKU B6848)—from APExBIO for use as a selective HM74A/GPR109A and GPR109B agonist. According to the product information, Acifran supports advanced studies of lipid metabolism regulation and receptor-ligand interactions. For further technical context, internal articles detail optimized protocols and the mechanistic role of Acifran in lipid signaling pathway research.